Affiliated Institutions
Related Publications
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Clinical studies with the Abl tyrosine kinase inhibitor STI-571 in chronic myeloid leukemia demonstrate that many patients with advanced stage disease respond initially but then...
Diagnosing and Managing Advanced Chronic Myeloid Leukemia
Clinical staging of chronic myeloid leukemia (CML) distinguishes between chronic phase (CP-CML), accelerated phase (AP-CML), and blastic phase (BP-CML), reflecting its natural h...
Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment
Abstract Targeting the tyrosine kinase activity ofBCR-ABL represents a very promising therapeutic strategy in chronic myeloid leukemia (CML). Despite strong efficacy of the tyro...
Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management
Disease overview : Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm with an incidence of 1–2 cases per 100,000 adults, and accounts for ∼15% of newly diagnosed ca...
Opportunities and challenges in the development of kinase inhibitor therapy for cancer
The success of the tyrosine kinase imatinib inhibitor (Gleevec, STI571) in treating chronic myeloid leukemia as well as other selected cancers has greatly increased optimism for...
Publication Info
- Year
- 2025
- Type
- article
- Pages
- JCO2502691-JCO2502691
- Citations
- 0
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
0
OpenAlex
Cite This
Matthew S. Davids
(2025).
BRUIN 313 and 314 Trials Open the Door for Noncovalent Bruton Tyrosine Kinase Inhibition as Initial Therapy for Chronic Lymphocytic Leukemia.
Journal of Clinical Oncology
, JCO2502691-JCO2502691.
https://doi.org/10.1200/jco-25-02691
Identifiers
- DOI
- 10.1200/jco-25-02691